Ashland launches permexa sodium caprate for oral biologics
The intestinal permeation enhancer supports scalable development of oral peptide therapies amid growing demand for non-injectable treatments.
See the latest news and media coverage for Ashland. We track all announcements, press releases, and industry mentions in real time, all in one place.
Specialty materials company
ashland.comLast updated
In short: Ashland reported a 7% sales increase in its third quarter, settled with activist Ancora Holdings, and explored a potential company sale.
The intestinal permeation enhancer supports scalable development of oral peptide therapies amid growing demand for non-injectable treatments.
Sales rose 7% to $497 million, volumes up 6%, and Adjusted EBITDA was $109 million, down 4%.
Peter Thomas and Allen Spizzo join the board, and a new Capital Allocation Advisory Committee is formed under a cooperation agreement with Ancora.
The webcast will be on July 29 with CEO and CFO participating.
On September 15, 2026, shares of Ashland Inc. (NYSE: ASH) rose nearly 1% following reports that the...
Ashland (ASH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings...
The chemical maker, which settled with an activist investor last month, is working with Citigroup and Lazard to engage with strategic and financial suitors.
The strike began after Ashland Specialty Chemicals proposed a new contract that removed benefits for...
Track Ashland and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Ashland and other trending companies.